Outcome Predictors in Patients With Severe Sepsis and Optimized Central Venous Oxygen Saturation

NCT ID: NCT01362829

Last Updated: 2011-06-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators perform a prospective observation study to search for the outcome predictors (ScvO2 and lactate) in patients with severe sepsis after admission to ICU.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Early goal-directed therapy in patients with severe sepsis or septic shock was found to provide survival benefit.It was thought that early optimization of ScvO2 within 6 hours in emergency department brought survival benefit to patients of septic shock or severe sepsis.On the other hand, early lactate clearance is associated with improved outcome in patients with severe sepsis or septic shock. In patients with severe sepsis and septic shock, those with low lactate clearance had poor prognosis, despite optimization of ScvO2. It is unknown if ScvO2 could still guide hemodynamic resuscitation after admission into ICU. The investigators perform a prospective observation study to see the correlation between ScvO2 and clinical outcome (including organ failure, disease severity, and survival) and the correlation between lactate and clinical outcome. Furthermore, if ScvO2 \>= 70% is still of prognostic significance in ICU, we will investigate the outcome in patients with high ScvO2 and high serum lactate levels, and to evaluate the clinical features of this patient population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with severe sepsis

Patients who are admitted to medical ICU with severe sepsis

Determined by intended physician

Intervention Type OTHER

We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Determined by intended physician

We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients who are admitted to medical intensive care units with severe sepsis or septic shock

Exclusion Criteria

* presence of acute cerebral vascular attack
* acute cardiogenic lung edema
* status asthmatics
* cardiac dysrhythmia as the primary diagnosis
* massive gastrointestinal bleeding
* epileptics
* drug overdose
* requirement of immediate surgery
* hematologic malignancies
* febrile neutropenia
* treatment with immunosuppressive agents before admission
* advanced malignancy and poor pre-admission performance status
* with inevitable short-term mortality or morbidity
* HIV infection
* refusal of consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Far Eastern Memorial Hospital

OTHER

Sponsor Role collaborator

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

National Taiwan University Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chong-Jen Yu, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital

Hou-Tai Chang, MD

Role: PRINCIPAL_INVESTIGATOR

Far Eastern Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Far Eastern Memorial Hospital

Taipei, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

098014-3

Identifier Type: OTHER

Identifier Source: secondary_id

200907064R

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.